



(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(48) Corrigendum issued on:
26.04.2023 Bulletin 2023/17

(45) Date of publication and mention
of the grant of the patent:
22.03.2023 Bulletin 2023/12

(21) Application number: **16861054.1**

(22) Date of filing: **31.10.2016**

(51) International Patent Classification (IPC):
A61K 31/455 ^(2006.01) **A61K 45/06** ^(2006.01)
A61P 25/28 ^(2006.01) **C07C 57/03** ^(2006.01)
C07C 57/30 ^(2006.01) **C07C 57/50** ^(2006.01)
A61P 25/00 ^(2006.01) **A61P 25/16** ^(2006.01)
A61K 31/192 ^(2006.01) **A61K 31/198** ^(2006.01)
A61K 9/00 ^(2006.01) **A61K 9/48** ^(2006.01)

(52) Cooperative Patent Classification (CPC):
(C-Sets available)
A61K 31/198; A61K 9/0043; A61K 9/0053;
A61K 31/192; A61K 31/455; A61K 45/06;
A61P 25/00; A61P 25/16; A61P 25/28;
A61K 9/0019; A61K 9/48; Y02A 50/30 (Cont.)

(86) International application number:
PCT/US2016/059770

(87) International publication number:
WO 2017/075607 (04.05.2017 Gazette 2017/18)

(54) **TREATMENT OF NERVOUS SYSTEM DISORDERS USING COMBINATIONS OF RXR AGONISTS AND THYROID HORMONES**

BEHANDLUNG VON ERKRANKUNGEN DES NERVENSYSTEMS MITHILFE VON
KOMBINATIONEN VON RXR-AGONISTEN UND SCHILDDRÜSENHORMONEN

TRAITEMENT DES TROUBLES DU SYSTÈME NERVEUX AU MOYEN DE COMBINAISONS
D'AGONISTES DE PXR ET D'HORMONES THYROÏDIENNES

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR

(30) Priority: **31.10.2015 US 201562249216 P**

(43) Date of publication of application:
05.09.2018 Bulletin 2018/36

(73) Proprietor: **IO Therapeutics, Inc.**
Spring, TX 77387 (US)

(72) Inventors:
• **CHANDRARATNA, Roshantha, A.**
San Juan Capistrano, CA 92675 (US)
• **SANDERS, Martin, E.**
Seattle, WA 98101 (US)

(74) Representative: **Murgitroyd & Company**
Murgitroyd House
165-169 Scotland Street
Glasgow G5 8PL (GB)

(56) References cited:
EP-A1- 2 322 147 EP-A1- 2 556 827
WO-A1-2015/059632 US-A1- 2004 147 611
US-A1- 2009 227 674 US-A1- 2009 227 674
US-A1- 2015 038 585

- **C. ASSAF ET AL: "Minimizing adverse side-effects of oral bexarotene in cutaneous T-cell lymphoma: an expert opinion", BRITISH JOURNAL OF DERMATOLOGY, vol. 155, no. 2, 1 August 2006 (2006-08-01), pages 261-266, XP055586558, UK ISSN: 0007-0963, DOI: 10.1111/j.1365-2133.2006.07329.x**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

- AI LING FU ET AL: "Thyroid hormone prevents cognitive deficit in a mouse model of Alzheimer's disease", NEUROPHARMACOLOGY., vol. 58, no. 4-5, 1 March 2010 (2010-03-01), pages 722-729, XP055593277, GB ISSN: 0028-3908, DOI: 10.1016/j.neuropharm.2009.12.020
- SHERMAN ET AL.: 'Central hypothyroidism associated with retinoid X receptor-selective ligands.' THE NEW ENGLAND JOURNAL OF MEDICINE, [Online] vol. 340, no. 14, 1999, pages 1075 - 1079, XP055379565 Retrieved from the Internet:
<URL:http://www.nejm.org/doi/pdf/10.1056/NEJM199904083401404> [retrieved on 2016-12-12]

(52) Cooperative Patent Classification (CPC): (Cont.)

C-Sets

A61K 31/192, A61K 2300/00;

A61K 31/198, A61K 2300/00;

A61K 31/455, A61K 2300/00